Reply to “Misleading impact of mitral regurgitation on the evaluation of left ventricular contractile function in heart failure with preserved ejection fraction”
We thank the authors for the interest in our recent review article.1 The points raised by the authors highlight some technical and pathophysiological limitations of left ventricular (LV) ejection fraction (LVEF) measurement, that is commonly used as a key parameter for evaluation of LV function and timing of mitral valve repair or replacement (MVR), due to its load dependency and its misleading overestimation of LV pump function in the presence of mitral regurgitation (MR). LVEF is calculated as (end-diastolic volume – end-systolic volume)/end-diastolic volume. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - May 7, 2024 Category: Cardiology Authors: Mauro Riccardi, Riccardo M. Inciardi Tags: Letter to the Editor Source Type: research
Heart Failure Society of America: The Heart of a Soulful Discipline
For me the journey began over lunch. There were no established pathways to a career in Heart Failure, so each of us meandered there on our own. I had come to Tufts Medical Center with a charge of building a Cardiac Nuclear Medicine Program, but my passion was rooted in physiology. My interests lay in pulmonary hypertension and right ventricular function, but since most patients with pulmonary hypertension had left heart failure, I used my tools to study that population and investigate emerging treatments. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - May 7, 2024 Category: Cardiology Authors: Marvin A. Konstam Tags: Perspectives Source Type: research
Highlights from the International Society for Heart and Lung Transplantation (ISHLT) 2024
Franz Kafka, arguably the city's most famous citizen, contended that Prague ‘never lets you go’ and in this sense it served as the perfect backdrop to the 44th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). From April 10th-13th, 2024, the advanced heart failure, heart transplant and mechanical circulatory support (MCS) communitie s presented the latest basic, translational and clinical science. We hope to present a snapshot of some of this exciting and innovative science and research, focusing on a number of compelling themes across the cardiac-related sessions. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - May 4, 2024 Category: Cardiology Authors: Emer Joyce, Jeff Teuteberg Tags: Perspectives Source Type: research
Heartfelt Advances: ACC 2024 Clinical Trials Spotlight-New Horizons in Heart Failure Management
The American College of Cardiology, 2024, (ACC.24) Annual Scientific Session offered a plethora of new clinical science within which were heart failure – centric data qualifying as transformative research and advances in clinical practice. Among the highlights were reaffirming trials, groundbreaking data, unanticipated results, and innovative therapeutic strategies with both null but informative data, and definitive outcomes. Regardless of the fi ndings, all of these data will lead to future work, either validating positive findings or further exploring null results. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - May 3, 2024 Category: Cardiology Authors: Jennifer Maning, Jonathan Hourmozdi, Sonu Abraham, Quentin Youmans, Jane Wilcox, Sanjiv Shah, Clyde Yancy Tags: Perspectives Source Type: research
My Journey as a Heart Transplantation Patient …and What I Want Providers to Know—Part III
JCF is honored to share this Patient Experience Series over the next three weeks. If you have not yet read the first and second parts of this series, you can do so here (https://doi.org/10.1016/j.cardfail.2024.04.005 and https://doi.org/10.1016/j.cardfail.2024.04.006). Part III and final segment of the series is below. The full story will be published in the May 2024 issue and online under our Patient and Caregiver Center at www.jcfonline.com. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - May 1, 2024 Category: Cardiology Authors: MARK BOORAS Source Type: research
My Journey as a Heart Transplantation Patient …and What I Want Providers to Know-Part III
JCF is honored to share this Patient Experience Series over the next three weeks. If you have not yet read the first and second parts of this series, you can do so here (URL XXXX). Part III and final segment of the series is below. The full story will be published in the May 2024 issue and online under our Patient and Caregiver Center at www.jcfonline.com. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - May 1, 2024 Category: Cardiology Authors: Mark Booras Source Type: research
High circulating dipeptidyl peptidase 3 predicts mortality and need for organ support in cardiogenic shock: An ancillary analysis of the ACCOST-HH trial
Cardiogenic shock (CS) can be defined as a state of persisting low cardiac output associated with insufficient organ perfusion. Acute myocardial infraction (AMI) is its most frequent cause although up to 50% of all CS might be related to other etiologies including acute decompensated heart failure, valvular abnormalities, severe arrhythmia, myocarditis, septic cardiomyopathy etc... (1,2). Despite contemporary management, CS is still burdened with high mortality ( ∼30-50% in-hospital mortality) and efforts to improve outcome are hampered by the difficulty of individual risk stratification and the lack of targetable pathwa...
Source: Journal of Cardiac Failure - April 29, 2024 Category: Cardiology Authors: Adrien Picod, Hugo Nordin, Dominik Jarczak, Tanja Zeller, Claire Oddos, Karine Santos, Oliver Hartmann, Antoine Herpain, Alexandre Mebazaa, Stefan Kluge, Feriel Azibani, Mahir Karakas Source Type: research
Sex-Based Differences in the Epidemiology, Clinical Characteristics, and Outcomes Associated with Worsening Heart Failure Events in a Learning Health System
Differences in demographics, risk factors, and clinical characteristics may contribute to variation in men and women in terms of prevalence, clinical setting, and outcomes associated with worsening heart failure (WHF) events. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 29, 2024 Category: Cardiology Authors: Chloe J. Leung, Ankeet S. Bhatt, Alan S. Go, Rishi V. Parikh, Elisha A. Garcia, Kathy C. Le, Deborah Low, Amanda R. Allen, Jesse K. Fitzpatrick, Sirtaz Adatya, Dana R. Sax, Parag Goyal, Anubodh S. Varshney, Alexander T. Sandhu, Shanshan E. Gustafson, Andr Source Type: research
Alcohol consumption and progression of heart failure in those at risk for or with pre-heart failure
People with heart risk factors such as high blood pressure, diabetes, obesity or high cholesterol, may develop extra strain on the heart over time because of these risk factors. We researched the association of low and moderate-high levels of alcohol intake, compared to no intake, with changes in the heart over time. We found that amongst participants with heart abnormalities, drinking the equivalent of more than a bottle of wine per week was associated with further negative changes in the heart or development of symptoms of heart failure. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 26, 2024 Category: Cardiology Authors: Bethany Wong, Ashe Moore, Ken McDonald, Mark Ledwidge Source Type: research
My Journey as a Heart Transplantation Patient …and What I Want Providers to Know: Part II
JCF is honored to share this Patient Experience Series over the next 3 weeks. If you have not yet read the first part of this series, you can do so here (https://doi.org/10.1016/j.cardfail.2024.04.005). Part II of the series is below. The full story will be published in the May 2024 issue and online under our Patient and Caregiver Center at www.jcfonline.com. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 26, 2024 Category: Cardiology Authors: Mark Booras Source Type: research
My Journey as a Heart Transplantation Patient …and What I Want Providers to Know: Part 1
JCF is honored to share this Patient Experience Series over the next 3 weeks. Part I is below. The full story will be published in the May 2024 issue and online under our Patient and Caregiver Center at www.jcfonline.com. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 24, 2024 Category: Cardiology Authors: Mark Booras Source Type: research
Sodium-Glucose Co-transporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have proven benefits on clinical outcomes in patients with heart failure (HF).1-6 However, this class of medications increases the risk of mycotic genital infections (MGIs) and urinary tract infections (UTIs), particularly within the first 3-6 months after their initiation.7,8,9 In the EMPEROR-Preserved and EMPEROR-Reduced trials, MGIs and UTIs were among the 3 most common adverse events in the empagliflozin group,1,2 highlighting the clinical relevance of these infections. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 24, 2024 Category: Cardiology Authors: Angela Duvalyan, Ricardo M. La Hoz, Darren K McGuire, Mark H. Drazner Tags: Review Article Source Type: research
Five-Year Experience From a Cardiovascular Physician and Advanced Practice Providers Leadership-Development Program
As payment and clinical-care models place increased emphasis on patient-centered care, multidisciplinary teams, public health, wellness, and social determinants of health, clinical leadership is increasingly recognized as being essential to high-quality, safe and efficient operations.1,2 (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 19, 2024 Category: Cardiology Authors: WARREN S. LEVY, CHRISTOPHER M. O'CONNOR Source Type: research
Five Year Experience from a Cardiovascular Physician and APP Leadership Development Program
As payment and clinical care models place increased emphasis on patient-centered care, multidisciplinary teams, public health, wellness, and social determinants of health, clinical leadership is increasingly recognized as essential to high quality, safe and efficient operations. (1,2) (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 19, 2024 Category: Cardiology Authors: Warren S. Levy Tags: Brief Report Source Type: research
Body Mass Index Distribution Among Patients with Heart Failure and Reduced Ejection Fraction: Implication for Future Trials
Obesity related heart failure with preserved ejection fraction (HFpEF) has been well described as a distinct phenotype associated with cardiac structural and functional alterations as well as a systemic proinflammatory milieu. Semaglutide, a long-acting glucagon like peptide (GLP)-1 receptor agonist, was recently assessed in patients with HF and an LVEF of ≥45% and obesity (without type 2 diabetes) in the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and Heart Failure with preserved Ejection Fraction) trial and was shown to improve symptoms, and exercise capacity, compared with placebo. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 16, 2024 Category: Cardiology Authors: Javed Butler, Ambica Nair, Muhammad Shahzeb Khan Tags: Research Letter Source Type: research
